CSPC Listed in 2023 Top 100 Chinese Chemical Pharmaceutical Enterprises

The 2024 China Medical and Health Industry Symbiosis Conference (MHIS), under the industry's spotlight, was inaugurated on June 25. Representatives from top-notch pharmaceutical industrial enterprises gathered in Huzhou to jointly promote and support this great event. The 2023 Top 100 Enterprises list in China's Pharmaceutical Industry was issued that night. Among them, the reveal of the "Top 100 Chinese Chemical Pharmaceutical Enterprises" was especially eye-catching. CSPC was listed again for its outstanding innovation strength and market leadership, ranking fourth.

The list of 2023 Top 100 Enterprises in China's Pharmaceutical Industry was initiated and hosted by Menet, China's leading platform of pharmaceutical and health information. It aims to set up a benchmark for domestic pharmaceutical industry enterprises to enhance their comprehensive strength and expand brand presence, demonstrate the excellence of the pharmaceutical brand industry, and guide the steady, rapid, and sustainable development of the pharmaceutical and health industry. To guide the industry towards proper and rigorous transformation and upgrading, Menet Research Institute, relying on the terminal pattern database exclusively developed and run by Menet in China for many years, selected the list in a more scientific, rigorous way from the two most important dimensions, namely, innovation driving force and professional promotion.

As a leader in the chemical drug industry, CSPC has adhered to the innovation-driven approach, committed to the R&D of innovative drugs, and made continuous efforts to this end. Our annual R&D investment reaches approximately 5 billion yuan, with double-digit growth yearly. We have 130+ innovative drug projects under development, 40+ of which are macromolecular drugs, 40+ micromolecular drugs, and 30+ new preparations. In the next five years, CSPC will have more than 50 innovative drugs applied for marketing. The continuous expansion of R&D pipelines represents our unremitting exploration of new disease fields. Currently, CSPC's innovation strength has demonstrated a global presence. With five R&D centers worldwide and high-end R&D teams of 2000+ members, we conduct scientific research and exploration for new technologies and new targets in new fields every day.

Ranking 4^th on the list of Top 100 Chinese Chemical Pharmaceutical Enterprises proves CSPC's leadership and comprehensive strength in the chemical drug industry. In the future, CSPC will adhere to its innovation and internationalization strategies and work together with medical institutions, scientific research institutes, pharmaceutical enterprises, and other parties around the world, to integrate global resources and promote drug innovation continuously, thereby making our contribution to global health.